BioCentury
DATA GRAPHICS | Data Byte

Platform companies serve notice among China’s future leaders

The strategy of in-licensing portfolios could be on its way out

November 17, 2021 1:49 AM UTC

Platform companies are taking hold in China, outnumbering and outraising in-licensing plays among the class of companies likely to spawn the next generation of bellwethers. 

In-licensing assets to kick-start a portfolio has been a cornerstone strategy for many of China’s leading therapeutics companies as the biotech ecosystem went from zero to 60 in record time. ...